Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Nicotine (transdermal) is a depending agent that is FDA approved for the treatment of Reducing withdrawal symptoms, including nicotine craving, associated with quitting smoking. Common adverse reactions include skin irritation, nasal irritation, nasal spray, oral irritation, dizziness, headache, insomnia.
There is limited information regarding Off-Label Guideline-Supported Use of Nicotine (transdermal) in adult patients.
There is limited information regarding Off-Label Non–Guideline-Supported Use of Nicotine (transdermal) in adult patients.
There is limited information regarding FDA-Labeled Use of Nicotine (transdermal) in pediatric patients.
There is limited information regarding Off-Label Guideline-Supported Use of Nicotine (transdermal) in pediatric patients.
There is limited information regarding Off-Label Non–Guideline-Supported Use of Nicotine (transdermal) in pediatric patients.
There is limited information regarding Nicotine (transdermal) Contraindications in the drug label.
There is limited information regarding Clinical Trial Experience of Nicotine (transdermal) in the drug label.
There is limited information regarding Postmarketing Experience of Nicotine (transdermal) in the drug label.
There is limited information regarding Nicotine (transdermal) Drug Interactions in the drug label.
Pregnancy Category (FDA): D
There is no FDA guidance on usage of Nicotine (transdermal) in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Nicotine (transdermal) in women who are pregnant.
There is no FDA guidance on use of Nicotine (transdermal) during labor and delivery.
There is no FDA guidance on the use of Nicotine (transdermal) with respect to nursing mothers.
There is no FDA guidance on the use of Nicotine (transdermal) with respect to pediatric patients.
There is no FDA guidance on the use of Nicotine (transdermal) with respect to geriatric patients.
There is no FDA guidance on the use of Nicotine (transdermal) with respect to specific gender populations.
There is no FDA guidance on the use of Nicotine (transdermal) with respect to specific racial populations.
There is no FDA guidance on the use of Nicotine (transdermal) in patients with renal impairment.
There is no FDA guidance on the use of Nicotine (transdermal) in patients with hepatic impairment.
There is no FDA guidance on the use of Nicotine (transdermal) in women of reproductive potentials and males.
There is no FDA guidance one the use of Nicotine (transdermal) in patients who are immunocompromised.
There is limited information regarding Monitoring of Nicotine (transdermal) in the drug label.
There is limited information regarding IV Compatibility of Nicotine (transdermal) in the drug label.
There is limited information regarding Chronic Overdose of Nicotine (transdermal) in the drug label.
There is limited information regarding Nicotine (transdermal) Pharmacology in the drug label.
There is limited information regarding Nicotine (transdermal) Mechanism of Action in the drug label.
There is limited information regarding Nicotine (transdermal) Structure in the drug label.
There is limited information regarding Pharmacodynamics of Nicotine (transdermal) in the drug label.
There is limited information regarding Pharmacokinetics of Nicotine (transdermal) in the drug label.
There is limited information regarding Nonclinical Toxicology of Nicotine (transdermal) in the drug label.
There is limited information regarding Clinical Studies of Nicotine (transdermal) in the drug label.
There is limited information regarding Nicotine (transdermal) Storage in the drug label.
{{#ask: Page Name::Nicotine (transdermal) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
{{#ask: Label Page::Nicotine (transdermal) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
There is limited information regarding Patient Counseling Information of Nicotine (transdermal) in the drug label.
There is limited information regarding Nicotine (transdermal) Brand Names in the drug label.
There is limited information regarding Nicotine (transdermal) Look-Alike Drug Names in the drug label.
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Label Page=Nicotine (transdermal) |Label Name=Nicotine (transdermal)02.png
}}
{{#subobject:
|Label Page=Nicotine (transdermal) |Label Name=Nicotine (transdermal)03.png
}}